Laura Orsolini
Laura Orsolini
Unit of Clinical Psychiatry, Department of Neurosciences/DIMSC, Polytechnic University of Marche
Verified email at
Cited by
Cited by
Novel psychoactive substances of interest for psychiatry
F Schifano, L Orsolini, G Duccio Papanti, JM Corkery
World Psychiatry 14 (1), 15-26, 2015
Understanding the complex of suicide in depression: from research to clinics
L Orsolini, R Latini, M Pompili, G Serafini, U Volpe, F Vellante, M Fornaro, ...
Psychiatry investigation 17 (3), 207, 2020
COVID-19 effect on mental health: patients and workforce
V Pereira-Sanchez, F Adiukwu, S El Hayek, DG Bytyši, JM Gonzalez-Diaz, ...
The Lancet Psychiatry 7 (6), e29-e30, 2020
Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors
D De Berardis, M Fornaro, A Valchera, M Cavuto, G Perna, M Di Nicola, ...
International journal of molecular sciences 19 (10), 2888, 2018
Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine
D De Berardis, G Rapini, L Olivieri, D Di Nicola, C Tomasetti, A Valchera, ...
Therapeutic advances in drug safety 9 (5), 237-256, 2018
Suicide during perinatal period: epidemiology, risk factors, and clinical correlates
L Orsolini, A Valchera, R Vecchiotti, C Tomasetti, F Iasevoli, M Fornaro, ...
Frontiers in psychiatry 7, 138, 2016
Alexithymia and suicide risk in psychiatric disorders: a mini-review
D De Berardis, M Fornaro, L Orsolini, A Valchera, A Carano, F Vellante, ...
Frontiers in psychiatry 8, 148, 2017
Mental health interventions during the COVID-19 pandemic: a conceptual framework by early career psychiatrists
R Ransing, F Adiukwu, V Pereira-Sanchez, R Ramalho, L Orsolini, ...
Asian journal of psychiatry 51, 102085, 2020
An update of safety of clinically used atypical antipsychotics
L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, ...
Expert opinion on drug safety 15 (10), 1329-1347, 2016
The prevalence and predictors of bipolar and borderline personality disorders comorbidity: systematic review and meta-analysis
M Fornaro, L Orsolini, S Marini, D De Berardis, G Perna, A Valchera, ...
Journal of affective disorders 195, 105-118, 2016
Infectious disease outbreak related stigma and discrimination during the COVID-19 pandemic: Drivers, facilitators, manifestations, and outcomes across the world
R Ransing, R Ramalho, R de Filippis, MI Ojeahere, R Karaliuniene, ...
Brain, behavior, and immunity 89, 555, 2020
Serotonin reuptake inhibitors and breastfeeding: a systematic review
L Orsolini, C Bellantuono
Human Psychopharmacology: Clinical and Experimental 30 (1), 4-20, 2015
Can COVID-19 related mental health issues be measured?
R Ransing, R Ramalho, L Orsolini, F Adiukwu, JM Gonzalez-Diaz, ...
Brain, behavior, and immunity 88, 32, 2020
Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts
L Orsolini, GD Papanti, G Francesconi, F Schifano
Cyberpsychology, Behavior, and Social Networking 18 (5), 296-300, 2015
Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces
L Orsolini, G Francesconi, D Papanti, A Giorgetti, F Schifano
Human Psychopharmacology: Clinical and Experimental 30 (4), 302-318, 2015
Targeting the noradrenergic system in posttraumatic stress disorder: a systematic review and meta-analysis of prazosin trials
DD Berardis, S Marini, N Serroni, F Iasevoli, C Tomasetti, ...
Current drug targets 16 (10), 1094-1106, 2015
Characteristics of deaths associated with kratom use
JM Corkery, P Streete, H Claridge, C Goodair, D Papanti, L Orsolini, ...
Journal of psychopharmacology 33 (9), 1102-1123, 2019
Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review
L Orsolini, S Chiappini, U Volpe, D De Berardis, R Latini, GD Papanti, ...
Medicina 55 (9), 525, 2019
Novel psychoactive substances: the pharmacology of stimulants and hallucinogens
F Schifano, GD Papanti, L Orsolini, JM Corkery
Expert review of clinical pharmacology 9 (7), 943-954, 2016
Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review
L Orsolini, F Sarchione, F Vellante, M Fornaro, I Matarazzo, G Martinotti, ...
Current neuropharmacology 16 (5), 583-606, 2018
The system can't perform the operation now. Try again later.
Articles 1–20